Denali recruits Genentech vet Carole Ho as CMO

Carole Ho

The Genentech vets behind South San Francisco-based Denali Therapeutics have recruited one of their former colleagues to join them as CMO and head of development. Carole Ho, former VP of early clinical development at Genentech, was tapped for the job. Denali turned heads a few months ago when it announced a whopping $217 million round to back their work on neurodegenerative diseases. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.